Ann Lee, Ph.D., serves as the Chief Technical Officer at PRIME Medicine Inc., a pioneering biotechnology company focused on developing innovative gene editing therapies. Dr. Lee's professional journey in the field of biotechnology is marked by her significant contributions to the development and application of advanced genetic technologies. She holds a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology (MIT), where her research focused on gene editing and its therapeutic potential. Her expertise in this area has been instrumental in guiding PRIME Medicine's mission to transform the treatment of genetic diseases. Prior to joining PRIME Medicine, Dr. Lee held several key positions at leading biotech firms, including a role as Senior Director of Research and Development at CRISPR Therapeutics, where she led multiple successful projects that advanced the company's gene editing platform. Her work has been published in numerous peer-reviewed journals, and she is recognized as a thought leader in the field of gene therapy. Dr. Lee's achievements have been acknowledged with several prestigious awards, including the Young Investigator Award from the American Society of Gene and Cell Therapy. As Chief Technical Officer at PRIME Medicine, Dr. Lee is responsible for overseeing the company's technical strategy and ensuring the successful development and implementation of its gene editing technologies. Her role involves close collaboration with the scientific and executive teams to drive innovation and bring new therapies to market. Under her leadership, PRIME Medicine is poised to make significant strides in the field of genetic medicine, offering hope to patients with previously untreatable genetic conditions.